Global Prostaglandin I2 Market Growth 2025-2031
Description
The global Prostaglandin I2 market size is predicted to grow from US$ 2853 million in 2025 to US$ 4171 million in 2031; it is expected to grow at a CAGR of 6.5% from 2025 to 2031.
Prostaglandin I2 (PGI), or prostacyclin, is one of the prostanoids, a group of local hormones that are best known for their roles in mediating inflammation.
The prostaglandin I2 (PGI2) market is driven by its critical role as a potent vasodilator and inhibitor of platelet aggregation, making it an essential therapeutic option for various cardiovascular conditions. PGI2, also known as prostacyclin, is used to treat pulmonary arterial hypertension (PAH), preventing blood clot formation and improving blood flow in affected patients. The increasing prevalence of PAH and the growing awareness of its therapeutic benefits contribute to market growth. Moreover, advancements in pharmaceutical research and biotechnology have led to the development of new formulations and delivery methods for PGI2, further expanding its application in cardiovascular medicine. However, the market also faces challenges, including the high cost of PGI2 therapy, which may limit patient access and affordability. Additionally, the need for continuous infusion in some cases and potential side effects, such as bleeding complications, can pose obstacles for widespread adoption. To succeed in this market, manufacturers must focus on cost-effectiveness, patient-friendly administration methods, and conducting extensive clinical trials to establish the safety and efficacy of PGI2 therapies for various cardiovascular conditions, ensuring its continued use as a critical treatment option.
LP Information, Inc. (LPI) ' newest research report, the “Prostaglandin I2 Industry Forecast” looks at past sales and reviews total world Prostaglandin I2 sales in 2024, providing a comprehensive analysis by region and market sector of projected Prostaglandin I2 sales for 2025 through 2031. With Prostaglandin I2 sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prostaglandin I2 industry.
This Insight Report provides a comprehensive analysis of the global Prostaglandin I2 landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Prostaglandin I2 portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Prostaglandin I2 market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prostaglandin I2 and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prostaglandin I2.
This report presents a comprehensive overview, market shares, and growth opportunities of Prostaglandin I2 market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Epoprostenol Sodium
Treprostinil
Iloprost
Beraprost Sodium
Segmentation by Application:
For Injection
For Oral
For Inhalation
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
United Therapeutics
J & J
GSK
Teva
Toray
Tide Pharma
Bayer AG
Key Questions Addressed in this Report
What is the 10-year outlook for the global Prostaglandin I2 market?
What factors are driving Prostaglandin I2 market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Prostaglandin I2 market opportunities vary by end market size?
How does Prostaglandin I2 break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Prostaglandin I2 (PGI), or prostacyclin, is one of the prostanoids, a group of local hormones that are best known for their roles in mediating inflammation.
The prostaglandin I2 (PGI2) market is driven by its critical role as a potent vasodilator and inhibitor of platelet aggregation, making it an essential therapeutic option for various cardiovascular conditions. PGI2, also known as prostacyclin, is used to treat pulmonary arterial hypertension (PAH), preventing blood clot formation and improving blood flow in affected patients. The increasing prevalence of PAH and the growing awareness of its therapeutic benefits contribute to market growth. Moreover, advancements in pharmaceutical research and biotechnology have led to the development of new formulations and delivery methods for PGI2, further expanding its application in cardiovascular medicine. However, the market also faces challenges, including the high cost of PGI2 therapy, which may limit patient access and affordability. Additionally, the need for continuous infusion in some cases and potential side effects, such as bleeding complications, can pose obstacles for widespread adoption. To succeed in this market, manufacturers must focus on cost-effectiveness, patient-friendly administration methods, and conducting extensive clinical trials to establish the safety and efficacy of PGI2 therapies for various cardiovascular conditions, ensuring its continued use as a critical treatment option.
LP Information, Inc. (LPI) ' newest research report, the “Prostaglandin I2 Industry Forecast” looks at past sales and reviews total world Prostaglandin I2 sales in 2024, providing a comprehensive analysis by region and market sector of projected Prostaglandin I2 sales for 2025 through 2031. With Prostaglandin I2 sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prostaglandin I2 industry.
This Insight Report provides a comprehensive analysis of the global Prostaglandin I2 landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Prostaglandin I2 portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Prostaglandin I2 market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prostaglandin I2 and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prostaglandin I2.
This report presents a comprehensive overview, market shares, and growth opportunities of Prostaglandin I2 market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Epoprostenol Sodium
Treprostinil
Iloprost
Beraprost Sodium
Segmentation by Application:
For Injection
For Oral
For Inhalation
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
United Therapeutics
J & J
GSK
Teva
Toray
Tide Pharma
Bayer AG
Key Questions Addressed in this Report
What is the 10-year outlook for the global Prostaglandin I2 market?
What factors are driving Prostaglandin I2 market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Prostaglandin I2 market opportunities vary by end market size?
How does Prostaglandin I2 break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
89 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Prostaglandin I2 by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Prostaglandin I2 by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
